Preview Mode Links will not work in preview mode

Mar 11, 2020

A special video supplement to a CME conference held during the 2019 San Antonio Breast Cancer Symposium featuring expert comments on the management of ER-positive breast cancer. Featuring perspectives from Dr Harold J Burstein.

  • Use of genomic classifiers to inform therapeutic decision-making for ER-positive localized breast cancer (00:00)
  • Prognostic and/or predictive utility of the various genomic assays for patients with node-negative and node-positive early breast cancer (03:23)
  • Implications of the TAILORx intermediate-risk cohort results for adjuvant treatment for pre- and postmenopausal patients with localized breast cancer (05:27)
  • Effects of prolonging adjuvant aromatase inhibitor therapy beyond 5 years on recurrence and cause-specific mortality (10:42)
  • NSABP-B-42: Ten-year results of extended adjuvant endocrine therapy with letrozole for postmenopausal women with ER-positive breast cancer who have completed previous adjuvant therapy with an aromatase inhibitor (AI) (12:28)
  • Optimizing the use of CDK4/6 inhibitors in the management of ER-positive metastatic breast cancer (mBC); overall survival findings and mechanisms of resistance (14:56)
  • Management of de novo ER-positive, HER2-negative mBC (18:22)
  • Choice of endocrine therapy partner for patients with de novo ER-positive, HER2-negative mBC (21:39)
  • Approach for patients with mBC and disease progression on an AI (24:04)
  • Selection and sequencing of CDK4/6 inhibitors in mBC; comparison of side-effect profiles (26:40)
  • Incidence, identification and prognostic significance of PI3K mutations in patients with ER-positive mBC (31:35)
  • Results of the Phase III SOLAR-1 trial evaluating alpelisib/fulvestrant versus fulvestrant alone for patients with ER-positive, HER2-negative advanced BC with or without a PIK3CA mutation after disease progression on first-line endocrine therapy; FDA approval for breast cancer with a PIK3CA mutation and current clinical role (33:27)
  • Spectrum, frequency and severity of toxicities observed with alpelisib (36:09)
  • Clinical experience with everolimus in mBC; potential for its use after disease progression on a CDK4/6 inhibitor (39:07)
  • Biologic rationale for evaluation of the Bcl-2 inhibitor venetoclax in ER-positive mBC (40:54)
  • Overview of the novel HER2-directed agents trastuzumab deruxtecan and tucatinib for HER2-positive mBC (44:00)
  • Dual targeted approach for patients with ER/PR-positive, HER2-positive mBC (46:40)
  • Investigation of other strategies designed to exploit the PI3K/AKT/mTOR pathway (50:06)
  • Early activity and safety data with the use of CDK4/6 inhibitors as neoadjuvant therapy; ongoing evaluation and potential clinical role (51:08)
  • Perspectives of Dr Burstein and Dr Love on the passing and legacy of the breast cancer revolutionary Dr Bernard Fisher (56:40)
  • Advances in the adjuvant treatment of HER2-positive and triple-negative breast cancer (1:02:24)

CME information and select publications